Skip to content
OpenCapital
Get started

Veracyte VCYT Biopharmaceutical and other revenue — Compensation expense

Similar metrics at other companies

Ligand Pharmaceuticals logo
LGNDDevelopment and Licensing of Biopharmaceutical Assets — Stock-Based Comp
$10.6M+35.2%
Labcorp Holdings logo
LHBiopharma Laboratory Services — Other Cost and Expense, Operating
$89.7M-0.3%
StepStone Group Inc. logo
STEPCompensation And Benefits Expense
$560.51M+64.6%
Spyre Therapeutics, Inc. logo
SYREReportable Segment — Compensation
$11.44M+63.7%
Brookfield Asset Management logo
BAMCompensation and employee benefits
$355M+37.1%
SEI Investments logo
SEICCompensation, benefits and other personnel
$206.32M+8.1%

Other financials

Income statement

See full
Revenue$139.1M+21.5%
Gross profit$101.2M+27.2%
Operating income$22.6M+680%
Net income$28.7M+307%
EPS (diluted)$0.35+289%

Balance sheet

See full
Cash & equivalents$264.8M+41.0%
Total debt$39.3M-22.1%
Total equity$1.3B+12.5%
Total assets$1.4B+9.2%

Cash flow

See full
Operating cash flow$35.2M+557%
CapEx$3.0M+62.8%
Free cash flow$32.3M+810%

Valuation

See full
Market cap$4.29B+10.7%

Profitability

See full
Gross margin70.9%+2.9pp
Operating margin14.3%+9.2pp
Net margin16.2%+9.1pp
FCF margin28.7%+11.7pp

Returns & leverage

See full
Return on equity6.9%+4.1pp
Debt / equity0×0.0×
Current ratio9.3×+4.2×

Where this comes from

Reported directly by Veracyte in its filing.

Tagged under the XBRL concept vcyt:CostOfRevenueCompensationExpense.

The official record: Veracyte’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veracyte's biopharmaceutical and other revenue — compensation expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Veracyte's biopharmaceutical and other revenue — compensation expense?
Veracyte (VCYT) reported biopharmaceutical and other revenue — compensation expense of $0 in Q1 2026.
How has Veracyte's biopharmaceutical and other revenue — compensation expense changed year-over-year?
Veracyte's biopharmaceutical and other revenue — compensation expense decreased by 100.0% year-over-year, from $1.24M to $0.
What is the long-term trend for Veracyte's biopharmaceutical and other revenue — compensation expense?
Over 3 years (2022 to 2025), Veracyte's biopharmaceutical and other revenue — compensation expense has grown at a -28.1% compound annual growth rate (CAGR), from $8.94M to $3.32M.
What does biopharmaceutical and other revenue — compensation expense mean?
This metric tracks the total personnel-related costs, including salaries, benefits, and stock-based compensation, specifically allocated to the biopharmaceutical and research services segment. It highlights the human capital investment required to maintain and scale the company's collaborative service offerings.